JP7680968B2 - Ｐｄ－１に対する抗体およびその使用方法 - Google Patents

Ｐｄ－１に対する抗体およびその使用方法 Download PDF

Info

Publication number
JP7680968B2
JP7680968B2 JP2021573799A JP2021573799A JP7680968B2 JP 7680968 B2 JP7680968 B2 JP 7680968B2 JP 2021573799 A JP2021573799 A JP 2021573799A JP 2021573799 A JP2021573799 A JP 2021573799A JP 7680968 B2 JP7680968 B2 JP 7680968B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021573799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536913A (ja
JP2022536913A5 (https=
JPWO2020252478A5 (https=
Inventor
ウェイン エイ． マラスコ
マシュー チャン
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2022536913A publication Critical patent/JP2022536913A/ja
Publication of JP2022536913A5 publication Critical patent/JP2022536913A5/ja
Publication of JPWO2020252478A5 publication Critical patent/JPWO2020252478A5/ja
Priority to JP2025078387A priority Critical patent/JP2025121997A/ja
Application granted granted Critical
Publication of JP7680968B2 publication Critical patent/JP7680968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
JP2021573799A 2019-06-14 2020-06-15 Ｐｄ－１に対する抗体およびその使用方法 Active JP7680968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078387A JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861638P 2019-06-14 2019-06-14
US62/861,638 2019-06-14
US201962884473P 2019-08-08 2019-08-08
US62/884,473 2019-08-08
PCT/US2020/037791 WO2020252478A2 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078387A Division JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022536913A JP2022536913A (ja) 2022-08-22
JP2022536913A5 JP2022536913A5 (https=) 2023-06-20
JPWO2020252478A5 JPWO2020252478A5 (https=) 2023-06-20
JP7680968B2 true JP7680968B2 (ja) 2025-05-21

Family

ID=73782142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573799A Active JP7680968B2 (ja) 2019-06-14 2020-06-15 Ｐｄ－１に対する抗体およびその使用方法
JP2025078387A Pending JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078387A Pending JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220249640A1 (https=)
EP (1) EP3983444A4 (https=)
JP (2) JP7680968B2 (https=)
AU (1) AU2020291946A1 (https=)
CA (1) CA3141927A1 (https=)
WO (1) WO2020252478A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7769007B2 (ja) * 2020-12-23 2025-11-12 イミュノウェイク インコーポレイテッド イムノサイトカイン及びその使用
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
WO2023076177A2 (en) * 2021-10-25 2023-05-04 Genvivo, Inc. Compositions and methods for therapeutic delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250303A (zh) 2016-12-19 2018-07-06 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US20100233154A1 (en) * 2008-10-08 2010-09-16 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
CA3101783C (en) * 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
US20230192839A1 (en) * 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
CN109422815A (zh) * 2017-08-28 2019-03-05 复旦大学 双特异性嵌合抗原受体c-Met/PD-1 scFv-CAR-T及其构建方法和应用
WO2020113224A2 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250303A (zh) 2016-12-19 2018-07-06 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
医薬・生活衛生局医薬品審査管理課[online], 審議結果報告書［販売名］キイトルーダ点滴静注20mg、同点滴静注100mg, 2018年11月30日[検索日：2024年5月20日], <https://www.pmda.go.jp/drugs/2019/P20190115001/170050000_22800AMX00696000_A100_1.pdf>

Also Published As

Publication number Publication date
AU2020291946A1 (en) 2022-01-06
EP3983444A2 (en) 2022-04-20
JP2022536913A (ja) 2022-08-22
CA3141927A1 (en) 2020-12-17
WO2020252478A3 (en) 2021-01-14
WO2020252478A2 (en) 2020-12-17
JP2025121997A (ja) 2025-08-20
EP3983444A4 (en) 2023-10-25
US20220249640A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP7377590B2 (ja) 抗ｃｄ３イプシロン抗体およびそれを使用する方法
EP3535299A1 (en) Anti-cd19 antibodies and methods of use thereof
US20250197496A1 (en) Bispecific antibody fusion molecules and methods of use thereof
JP2024511137A (ja) Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
JP2026048871A (ja) Ｐｄ－ｌ１に対する抗体およびその使用方法
JP7680968B2 (ja) Ｐｄ－１に対する抗体およびその使用方法
AU2023362569A1 (en) Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
AU2017300788A1 (en) Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
JP2024541476A (ja) Ｃｔｌａ－４に対する抗体及びその使用方法
JP2025527491A (ja) Ｃｌｄｎ４に対する抗体及びその使用方法
KR20250108093A (ko) Msln에 대한 항체 및 이의 사용 방법
JP7680967B2 (ja) Ｐｄ－１に対する抗体およびその使用方法
WO2025171401A2 (en) Antibodies against cd99 and methods of use thereof
HK40125012A (zh) 针对cldn4的抗体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250509

R150 Certificate of patent or registration of utility model

Ref document number: 7680968

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150